Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Association of CD4+CD25+FoxP3+ regulatory T cells with natural course of childhood chronic immune thrombocytopenic purpura

  • Son, Bo Ra (Department of Laboratory Medicine, Chungbuk National University College of Medicine) ;
  • Kim, Ji Yoon (Department of Pediatrics, Kyungpook National University School of Medicine)
  • 투고 : 2015.04.20
  • 심사 : 2015.05.07
  • 발행 : 2015.05.10
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The purpose of this study was to determine the frequency of $CD4^+CD25^+FoxP3^+$ regulatory T cells (Treg) in the peripheral blood of patients with childhood chronic immune thrombocytopenic purpura (ITP) exhibiting thrombocytopenia and spontaneous remission. The findings of this study indicate the possibility of predicting spontaneous recovery and pathogenesis of childhood chronic ITP. Methods: Eleven children with chronic ITP (seven thrombocytopenic and four spontaneous remission cases; mean age, 8.8 years; range, 1.7-14.9 years) were enrolled in this study. Five healthy children and eight healthy adults were included as controls. The frequency of Treg was evaluated by flow cytometry in the peripheral blood. Results: In this study, four patients (36%) achieved spontaneous remission within 2.8 years (mean year; range, 1.0-4.4 years). The frequency of Treg was significantly lower in patients with persisting thrombocytopenia ($0.13%{\pm}0.09%$, P<0.05), than that in the patients with spontaneous remission ($0.30%{\pm}0.02%$), healthy adults controls ($0.55%{\pm}0.44%$), and healthy children controls ($0.46%{\pm}0.26%$). A significantly positive correlation was found between the frequency of Treg and the platelet count in children. Conclusion: These data suggest that a lower frequency of Treg contributes to the breakdown of self-tolerance, and may form the basis for future development of specific immunomodulatory therapies. Furthermore, Treg frequency has prognostic implication toward the natural course and long-term outcomes of childhood chronic ITP.

키워드

참고문헌

  1. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849-59. https://doi.org/10.1038/nri2889
  2. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 2007;38:112-21. https://doi.org/10.1007/s12026-007-0022-2
  3. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-87. https://doi.org/10.1016/j.cell.2008.05.009
  4. Yazdanbakhsh K, Zhong H, Bao W. Immune dysregulation in immune thrombocytopenia. Semin Hematol 2013;50 Suppl 1:S63-7. https://doi.org/10.1053/j.seminhematol.2013.03.011
  5. Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2010;2010:377-84. https://doi.org/10.1182/asheducation-2010.1.377
  6. Imbach P, Kuhne T, Muller D, Berchtold W, Zimmerman S, Elalfy M, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006;46:351-6.. https://doi.org/10.1002/pbc.20453
  7. Bennett CM, Tarantino M. Chronic immune thrombocytopenia in children: epidemiology and clinical presentation. Hematol Oncol Clin North Am 2009;23:1223-38. https://doi.org/10.1016/j.hoc.2009.08.002
  8. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008. https://doi.org/10.1056/NEJMra010501
  9. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.
  10. Lazarus AH, Semple JW, Cines DB. Innate and adaptive immunity in immune thrombocytopenia. Semin Hematol 2013;50 Suppl 1:S68-70. https://doi.org/10.1053/j.seminhematol.2013.03.012
  11. Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program 2012;2012:306-12.
  12. Rosthoj S, Rajantie J, Treutiger I, Zeller B, Tedgard U, Henter JI, et al. Duration and morbidity of chronic immune thrombocytopenic purpura in children: five-year follow-up of a Nordic cohort. Acta Paediatr 2012;101:761-6. https://doi.org/10.1111/j.1651-2227.2012.02671.x
  13. Heitink-Polle KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood 2014;124:3295-307. https://doi.org/10.1182/blood-2014-04-570127
  14. Jayabose S, Levendoglu-Tugal O, Ozkaynkak MF, Visintainer P, Sandoval C. Long-term outcome of chronic idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol 2004;26:724-6. https://doi.org/10.1097/00043426-200411000-00007
  15. Yacobovich J, Revel-Vilk S, Tamary H. Childhood immune thrombocytopenia: who will spontaneously recover? Semin Hematol 2013;50 Suppl 1:S71-4. https://doi.org/10.1053/j.seminhematol.2013.03.013
  16. Andersson PO, Stockelberg D, Jacobsson S, Wadenvik H. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000;79:507-13. https://doi.org/10.1007/s002770000177
  17. Shim YJ, Kim UH, Suh JK, Lee KS. Natural course of childhood chronic immune thrombocytopenia using the revised terminology and definitions of the international working group: a single center experience. Blood Res 2014;49:187-91. https://doi.org/10.5045/br.2014.49.3.187
  18. Godeau B. Immune thrombocytopenic purpura: major progress in knowledge of the pathophysiology and the therapeutic strategy, but still a lot of issues. Presse Med 2014;43(4 Pt 2):e47-8. https://doi.org/10.1016/j.lpm.2014.02.010
  19. Nishimoto T, Kuwana M. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol 2013;50 Suppl 1:S43-9. https://doi.org/10.1053/j.seminhematol.2013.03.018
  20. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-4. https://doi.org/10.1038/nm921
  21. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86. https://doi.org/10.1182/blood-2009-06-225565
  22. Michel M. Immune thrombocytopenia nomenclature, consensus reports, and guidelines: what are the consequences for daily practice and clinical research? Semin Hematol 2013;50 Suppl 1:S50-4. https://doi.org/10.1053/j.seminhematol.2013.03.008
  23. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica 2008;93:98-103. https://doi.org/10.3324/haematol.11582

피인용 문헌

  1. Prognostic Significance of IL-10 in Childhood Chronic Immune Thrombocytopenic Purpura vol.23, pp.1, 2016, https://doi.org/10.15264/cpho.2016.23.1.28
  2. Clinical Course of Childhood Immune Thrombocytopenic Purpura and Analysis Predicting Factor of Prognosis vol.24, pp.2, 2015, https://doi.org/10.15264/cpho.2017.24.2.88
  3. Low-dose chidamide restores immune tolerance in ITP in mice and humans vol.133, pp.7, 2015, https://doi.org/10.1182/blood-2018-05-847624
  4. Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia vol.26, pp.1, 2021, https://doi.org/10.1080/16078454.2020.1856511